Pfizer Inc. is reupping a three-year, $9.5 million research collaboration with the University of California’s QB3 institute, but this time it is bringing money for startup life sciences companies to the table.
The world’s largest drug marketer and the California Institute for Quantitative Biosciences, or QB3, are expected to announce Friday that they will renew and expand the deal, which has led to 22 joint projects at UC San Francisco, UC Berkeley and UC Santa Cruz. One project was licensed by Pfizer.
No comments:
Post a Comment